Compare Enveric Biosciences Inc (ENVB) vs T Rowe Price Group Inc (TROW) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Enveric Biosciences Inc vs T Rowe Price Group Inc — how do they compare? Enveric Biosciences Inc trades at $1.44 (market cap $6.80M), while T Rowe Price Group Inc trades at $105.24 (market cap $22.23B). The key difference: T Rowe Price Group Inc is far larger — about 3269.1× Enveric Biosciences Inc's market cap, and T Rowe Price Group Inc pays a 4.99% dividend while Enveric Biosciences Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold Enveric Biosciences Inc for 14 Days and T Rowe Price Group Inc for 115 Days on average.
| ENVB | TROW | |
|---|---|---|
Market Cap | $6.80M | $22.23B |
Volume | 64,867 | 2,834,949 |
Sector | Health | Financials |
52-Week High | $10.80 | $121.68 |
52-Week Low | $1.27 | $86.19 |
Typical Hold Time | 14 Days | 115 Days |
Enterprise Value | -$1.49M | $19.43B |
Dividend Yield | — | 4.99% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ENVB trades at $1.45, down 3.01% on the day, with a bearish technical signal driven by moving averages. The company reported no revenue in 2025 and a net loss of $8.77 million, though it has consistently beaten quarterly EPS expectations. Recent positive developments include a new U.S. patent allowance for its non-hallucinogenic mescaline derivatives and participation in investor conferences.
The outlook is mixed; analyst consensus is 75% buy with strong earnings beats, but high negative ROE/ROA and operational cash burn pose significant risks. Investment opportunity hinges on successful drug development, while key risks include funding needs and clinical trial outcomes.
T. Rowe Price Group (TROW) trades at $104.07, showing modest daily gains of 0.45%. The stock presents mixed signals with bearish technical indicators but strong fundamentals including a low P/E of 10.46 and robust profitability metrics. Recent earnings show two consecutive beats, with Q3 2026 results pending. The company maintains solid cash flow generation and recently announced a $1.30 dividend payment for September 2026, continuing its 40-year dividend growth streak.
TROW offers value characteristics with attractive valuation multiples and consistent dividend growth, though technical weakness and mixed analyst sentiment suggest near-term caution. Upside potential exists to the $112 consensus target, but investors face risks from market-sensitive revenue streams and ongoing net outflows despite AUM growth to $1.90 trillion as of August 2026.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Enveric Biosciences Inc
Enveric Biosciences is a biotechnology company focused on developing next-generation psychedelic-inspired therapies for mental health and neuropsychiatric disorders.
Read more on ENVB →About T Rowe Price Group Inc
T. Rowe Price provides asset-management services for individual and institutional investors. It offers a broad range of no-load U.S. and international stock, hybrid, bond, and money market funds. At the end of August 2022, the firm had $1.339 trillion in managed assets, composed of equity (54%), balanced (30%), fixed-income (13%), and alternatives (3%) offerings. Approximately two thirds of the company's managed assets are held in retirement-based accounts, which provides T. Rowe Price with a somewhat stickier client base than most of its peers. The firm also manages private accounts, provides retirement planning advice, and offers discount brokerage and trust services. The company is primarily a U.S.-based asset manager, deriving just under 10% of its AUM from overseas.
Read more on TROW →
